This company is no longer active
GRPH Stock Overview
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Graphite Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.26 |
| 52 Week High | US$22.62 |
| 52 Week Low | US$2.01 |
| Beta | 0.20 |
| 1 Month Change | 654.58% |
| 3 Month Change | 831.38% |
| 1 Year Change | 861.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 20.32% |
Recent News & Updates
Recent updates
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Sep 20
We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely
Jun 02Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Feb 01Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Oct 05Graphite Bio doses first patient with GPH101 for sickle cell disease
Aug 11Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Jun 22Graphite Bio: Selling For Much Less Than Net Cash
May 25Graphite Bio: An Important Stock To Track In The Gene Editing Space
Nov 18Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans
Sep 25Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr
Aug 30Shareholder Returns
| GRPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 539.7% | -2.0% | -2.5% |
| 1Y | 861.6% | -8.7% | 21.6% |
Return vs Industry: GRPH exceeded the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: GRPH exceeded the US Market which returned 31.2% over the past year.
Price Volatility
| GRPH volatility | |
|---|---|
| GRPH Average Weekly Movement | 166.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GRPH's share price has been volatile over the past 3 months.
Volatility Over Time: GRPH's weekly volatility has increased from 82% to 166% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Kim Drapkin | graphitebio.com |
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
Graphite Bio, Inc. Fundamentals Summary
| GRPH fundamental statistics | |
|---|---|
| Market cap | US$190.43m |
| Earnings (TTM) | -US$124.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.4x
P/E RatioIs GRPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$124.65m |
| Earnings | -US$124.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GRPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/21 02:41 |
| End of Day Share Price | 2024/03/21 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Graphite Bio, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Gregory Harrison | BofA Global Research |
| Yun Zhong | BTIG |